Literature DB >> 19074904

250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.

Andrew J Dunbar1, Lukasz P Gondek, Christine L O'Keefe, Hideki Makishima, Manjot S Rataul, Hadrian Szpurka, Mikkael A Sekeres, Xiao Fei Wang, Michael A McDevitt, Jaroslaw P Maciejewski.   

Abstract

Two types of acquired loss of heterozygosity are possible in cancer: deletions and copy-neutral uniparental disomy (UPD). Conventionally, copy number losses are identified using metaphase cytogenetics, whereas detection of UPD is accomplished by microsatellite and copy number analysis and as such, is not often used clinically. Recently, introduction of single nucleotide polymorphism (SNP) microarrays has allowed for the systematic and sensitive detection of UPD in hematologic malignancies and other cancers. In this study, we have applied 250K SNP array technology to detect previously cryptic chromosomal changes, particularly UPD, in a cohort of 301 patients with myelodysplastic syndromes (MDS), overlap MDS/myeloproliferative disorders (MPD), MPD, and acute myeloid leukemia. We show that UPD is a common chromosomal defect in myeloid malignancies, particularly in chronic myelomonocytic leukemia (CMML; 48%) and MDS/MPD-unclassifiable (38%). Furthermore, we show that mapping minimally overlapping segmental UPD regions can help target the search for both known and unknown pathogenic mutations, including newly identified missense mutations in the proto-oncogene c-Cbl in 7 of 12 patients with UPD11q. Acquired mutations of c-Cbl E3 ubiquitin ligase may explain the pathogenesis of a clonal process in a subset of MDS/MPD, including CMML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074904      PMCID: PMC2668538          DOI: 10.1158/0008-5472.CAN-08-2754

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  Epigenetics and human disease.

Authors:  Yong-Hui Jiang; Jan Bressler; Arthur L Beaudet
Journal:  Annu Rev Genomics Hum Genet       Date:  2004       Impact factor: 8.929

2.  RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.

Authors:  C B Thien; F Walker; W Y Langdon
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

3.  Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.

Authors:  Robert Kralovics; Yongli Guan; Josef T Prchal
Journal:  Exp Hematol       Date:  2002-03       Impact factor: 3.084

4.  Evaluation and classification of RING-finger domains encoded by the Arabidopsis genome.

Authors:  Peter Kosarev; Klaus F X Mayer; Christian S Hardtke
Journal:  Genome Biol       Date:  2002-03-14       Impact factor: 13.583

5.  Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity.

Authors:  D P Bonita; S Miyake; M L Lupher; W Y Langdon; H Band
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

Review 6.  Mechanisms leading to uniparental disomy and their clinical consequences.

Authors:  W P Robinson
Journal:  Bioessays       Date:  2000-05       Impact factor: 4.345

7.  An efficient procedure for genotyping single nucleotide polymorphisms.

Authors:  S Ye; S Dhillon; X Ke; A R Collins; I N Day
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

8.  Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl.

Authors:  C B Thien; W Y Langdon
Journal:  Oncogene       Date:  1997-12-11       Impact factor: 9.867

9.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Authors:  S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 10.  Stem cells and cancer; the polycomb connection.

Authors:  Merel E Valk-Lingbeek; Sophia W M Bruggeman; Maarten van Lohuizen
Journal:  Cell       Date:  2004-08-20       Impact factor: 41.582

View more
  118 in total

1.  Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.

Authors:  Thomas Ernst; Andrew Chase; Katerina Zoi; Katherine Waghorn; Claire Hidalgo-Curtis; Joannah Score; Amy Jones; Francis Grand; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Translating cancer 'omics' to improved outcomes.

Authors:  Emily A Vucic; Kelsie L Thu; Keith Robison; Leszek A Rybaczyk; Raj Chari; Carlos E Alvarez; Wan L Lam
Journal:  Genome Res       Date:  2012-02       Impact factor: 9.043

3.  NF1 inactivation in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Peter Ouillette; Yin Wang; Yan Liu; Whitney Wright; Diane Roulston; Anjali Purkayastha; Amanda Dressel; Judith Karp; Paula Bockenstedt; Ammar Al-Zoubi; Moshe Talpaz; Lisa Kujawski; Yang Liu; Kerby Shedden; Sajid Shakhan; Cheng Li; Harry Erba; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

Review 4.  Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Authors:  Stephen C Kales; Philip E Ryan; Marion M Nau; Stanley Lipkowitz
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

5.  Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Harry Erba; Peter Ouillette; Diane Roulston; Anjali Purkayastha; Judith Karp; Moshe Talpaz; Lisa Kujawski; Sajid Shakhan; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Blood       Date:  2010-08-20       Impact factor: 22.113

6.  Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.

Authors:  Scott A Nadeau; Wei An; Bhopal C Mohapatra; Insha Mushtaq; Timothy A Bielecki; Haitao Luan; Neha Zutshi; Gulzar Ahmad; Matthew D Storck; Masashi Sanada; Seishi Ogawa; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

7.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

8.  Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.

Authors:  Christopher J Walker; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Krzysztof Mrózek; Sandya Liyanarachchi; Chi Song; Deedra Nicolet; James S Blachly; Marius Bill; Dimitrios Papaioannou; Christopher C Oakes; Brian Giacopelli; Luke K Genutis; Sophia E Maharry; Shelley Orwick; Kellie J Archer; Bayard L Powell; Jonathan E Kolitz; Geoffrey L Uy; Eunice S Wang; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield
Journal:  Clin Cancer Res       Date:  2019-08-02       Impact factor: 12.531

9.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

Review 10.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.